1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
Authors:
- Y.Y. JanjigianYJY.Y. Janjigian
- A. KawazoeAKA. Kawazoe
- Y. BaiYBY. Bai
- J. XuJXJ. Xu
- S. LonardiSLS. Lonardi
- J-P. MetgesJMJ-P. Metges
- P.E. Yanez WeberPWP.E. Yanez Weber
- L.S. WyrwiczLWL.S. Wyrwicz
- L. ShenLSL. Shen
- Y.V. OstapenkoYOY.V. Ostapenko
- M. BiliciMBM. Bilici
- H.C. ChungHCH.C. Chung
- 17 September 2024
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 35, S877-S878